| abstract |
The present invention provides vaccines for the prophylactic or therapeutic treatment of tumors in mammals, as well as methods of using such vaccines, including treating tumors and generating CTL responses. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluent. Wherein the particles comprise a metal and / or a semiconductor atom; And a plurality of ligands covalently bonded to the core, wherein the plurality of at least first ligands comprises a carbohydrate moiety covalently bonded to the core through a first linker, wherein the plurality Wherein at least a second ligand comprises an epitope peptide covalently bonded to the core via a second linker, wherein the second linker comprises a peptide moiety and a non-peptide moiety, wherein the peptide moiety comprises a sequence X 1 X 2 Z 1 , wherein X 1 is an amino acid selected from A and G; X 2 is an amino acid selected from A and G; Z 1 is Y and F. < / RTI > |